CJC-1295 vs Ipamorelin: A Research Comparison

CJC-1295 (with DAC) is built on the GHRH(1-29) backbone — the bioactive N-terminal fragment of native GHRH — with three engineering modifications. First, four amino acid substitutions confer resistance to dipeptidyl peptidase-IV (DPP-4) cleavage. Second, a maleimidopropionic-acid (MPA) group attached at Lys30 reacts with the free thiol of circulating albumin (Cys34), forming a covalent adduct. Third, the resulting albumin-bound complex is protected from renal clearance and proteolysis, extending the reported plasma half-life to approximately 8 days.^[1][2] Mechanistically, CJC-1295 is a GHRH receptor agonist at the anterior pituitary, signaling through Gαs/cAMP/PKA to drive somatotroph GH release. Because the DAC-bound circulating reservoir provides continuous low-level GHRH-receptor stimulation, GH and IGF-1 elevation is sustained rather than pulsatile in research models.

Ipamorelin is a 5-amino-acid synthetic peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts on the growth-hormone-secretagogue receptor 1a (GHS-R1a), the same receptor that binds endogenous ghrelin. Its mechanism is therefore distinct from CJC-1295 — it is a GHRP-class secretagogue, not a GHRH analog. Ipamorelin signaling at GHS-R1a is via Gαq/PLC/IP3 coupling, producing a sharp acute somatotroph GH release pulse without the prolonged elevation characteristic of long-acting GHRH analogs. A defining selectivity feature is that Ipamorelin produces no measurable elevation of cortisol or prolactin in research models — distinguishing it from earlier GHRP-class compounds.^[3][4]

The mechanistic point of difference is therefore receptor-class. CJC-1295 acts on GHRH-R; Ipamorelin acts on GHS-R1a. Because the two receptors converge on the somatotroph but use different intracellular signaling cascades (Gαs vs Gαq), simultaneous research stimulation produces a measurable GH-release synergy in published research, which is why the two compounds are commonly studied together.

CJC-1295 is most-cited in research designs requiring sustained GHRH-receptor stimulation, including long-duration GH-axis research, IGF-1 modulation studies, body-composition research in animal models, and as the GHRH-class reference compound in dual-secretagogue research. Its 8-day reported half-life makes it useful in research formats where weekly or twice-weekly research dosing is preferred over multiple-times-per-day designs.

Ipamorelin is most-cited in research designs requiring a selective GHRP-class tool compound — research isolating GHS-R1a signaling, GH-pulse-architecture research, body-composition research in animal models, GI-motility research (GHS-R1a is expressed in enteric neurons and Ipamorelin is studied in motility-recovery models), and bone-density research in animal models. Its lack of cortisol and prolactin elevation makes it a particularly clean tool compound when those endpoints must remain unconfounded.

The two peptides are most-cited together as a research stack. The pairing exploits the receptor-class difference: simultaneous stimulation of GHRH-R (CJC-1295) and GHS-R1a (Ipamorelin) produces a measurable synergistic GH release in published research, larger than either compound alone.^[5]